The shadow of generic rivalry has consistently loomed around copyright’s famous drug, Sildenafil, triggering questions about the outlook of related medicinal ventures. While early times saw substantial gains, the patent lapse has allowed the door for less expensive alternatives, potentially diminishing revenue and creating a real risk for stakeho